title: Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees.
abstract: To date, the Centre d'Etude Polymorphism Humain (CEPH) cell line model has only been used as a pharmacogenomic tool to evaluate which genes are responsible for the disparity in response to a single drug. The purpose of this study was demonstrate the model's ability to establish a specific pattern of quantitative trait loci (QTL) related to a shared mechanism for multiple structurally related drugs, the camptothecins, which are Topoisomerase 1 inhibitors. A simultaneous screen of six camptothecin analogues for in vitro sensitivity in the CEPH cell lines resulted in cytotoxicity profiles and orders of potency which were in agreement with the literature. For all camptothecins studied, heritability estimates for cytotoxic response averaged 23.1 ± 2.6%. Nonparametric linkage analysis was used to identify a relationship between genetic markers and response to the camptothecins. Ten QTLs on chromosomes 1, 3, 5, 6, 11, 12, 16 and 20 were identified as shared by all six camptothecin analogues. In a separate validation experiment, nine of the ten QTLs were replicated at the significant and suggestive levels using three additional camptothecin analogues. To further refine this list of QTLs, another validation study was undertaken and seven of the nine QTLs were independently replicated for all nine camptothecin analogues. This is the first study using the CEPH cell lines that demonstrates that a specific pattern of QTLs could be established for a class of drugs which share a mechanism of action. Moreover, it is the first study to report replication of linkage results for drug-induced cytotoxicity using this model. The QTLs, which have been identified as shared by all camptothecins and replicated across multiple datasets, are of considerable interest; they harbor genes related to the shared mechanism of action for the camptothecins, which are responsible for variation in response.
authors.affiliation: Division of Pharmacotherapy and Experimental Therapeutics, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
authors.forename: Venita Gresham
authors.initials: VG
authors.lastname: Watson
authors.forename: Alison
authors.initials: A
authors.lastname: Motsinger-Reif
authors.forename: Nicholas E
authors.initials: NE
authors.lastname: Hardison
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Peters
authors.forename: Tammy M
authors.initials: TM
authors.lastname: Havener
authors.forename: Lorraine
authors.initials: L
authors.lastname: Everitt
authors.forename: James Todd
authors.initials: JT
authors.lastname: Auman
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Comins
authors.forename: Howard L
authors.initials: HL
authors.lastname: McLeod
mesh_terms: D002166:Camptothecin / Q000009:adverse effects*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002874:Chromosome Mapping; D008040:Genetic Linkage / Q000187:drug effects; D006801:Humans; D020128:Inhibitory Concentration 50; D010375:Pedigree; D040641:Quantitative Trait Loci / Q000235:genetics; D059004:Topoisomerase I Inhibitors / Q000009:adverse effects*
chemical_list: D059004:Topoisomerase I Inhibitors; D002166:Camptothecin